Abstract: An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like.
Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
April 15, 2014
Assignee:
North Carolina State University
Inventors:
Paul F. Agris, Christopher D. J. Pearce, Lloyd G. Mitchell
Abstract: The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits.
Type:
Grant
Filed:
March 24, 2011
Date of Patent:
April 15, 2014
Assignee:
Abbott Laboratories
Inventors:
Frank C. Grenier, Ryan F. Workman, Hina N. Syed, Salman Ali
Abstract: Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject.
Type:
Grant
Filed:
June 22, 2012
Date of Patent:
April 8, 2014
Assignee:
Quidel Corporation
Inventors:
Nikol Lee De Forest, John Tamerius, Noah Nasser, Patrick Sexton
Abstract: A method for dissociating avidin or streptavidin efficiently from a biotin derivative, thereby making it possible to isolate a target material efficiently under a mild condition in a short period, and a dissociation agent for use thereof, are provided. The method for dissociating avidin or streptavidin from a biotin derivative, includes mixing a combination of avidin or streptavidin with desthiobiotin with a water-soluble polymer to which biotin or a derivative thereof is bound.
Abstract: Methods are disclosed to detect, characterize, measure, and quantitate human and humanized antibodies, and their conjugates, present in pre-clinical animal biological samples, including plasma/serum and tissue samples.
Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
March 25, 2014
Assignee:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Klaus-Dieter Preuss, Michael Pfreundschuh
Abstract: Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.
Abstract: The present invention discloses methods for detecting the presence of a complex between a first reagent and a second reagent in solution. In particular, the invention provides methods for qualitative or quantitative detection of an analyte or its specific binding partner in complex biological samples. The invention further discloses algorithms using summary rate changes at selected wavelengths in the absorbance spectra of colloidal metal-labeled analytes or specific binding partners to identify intermolecular interactions between the analyte and its binding partner.
Abstract: This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.
Abstract: The present invention pertains to the field of tools for ensuring manufacture of polypeptides and quality control. Specifically, it relates to a method for determining the amount of processed (active) neurotoxin polypeptides in a solution comprising processed neurotoxin polypeptides and partially processed or unprocessed neurotoxin polypeptides. The present invention further relates to a device for determining the amount of neurotoxin polypeptides and a kit adapted to carry out the method of the present invention.
Abstract: Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result.
Type:
Grant
Filed:
December 3, 2009
Date of Patent:
February 18, 2014
Assignee:
Abbott Laboratories
Inventors:
Maciej Adamczyk, Jefffrey R. Brashear, Phillip G. Mattingly
Abstract: Disclosed is a method for a rapid test. In accordance with an embodiment, a particle reagent is placed into a separate sample or reagent receptacle or test tube, in which the particle reagent reacts with one or several analytes in the liquid sample, and the particle reagent is put into contact with the rapid test device, in which a visible signal is formed by the particle reagent.
Type:
Grant
Filed:
August 10, 2006
Date of Patent:
January 21, 2014
Assignee:
Oy Reagena Ltd.
Inventors:
Ilpo Kuronen, Ilkka Mononen, Markku Parviainen
Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
Abstract: This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.
Abstract: The present invention relates to a method for determining or predicting the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
Type:
Grant
Filed:
October 25, 2011
Date of Patent:
January 7, 2014
Assignee:
Medizinische Universitat Innsbruck
Inventors:
Florian Kronenberg, Barbara Kollerits, Danilo Fliser
Abstract: The present invention relates to a method for diagnosing cancer using information on aberrant glycosylation of glycoproteins, which is related with cancer progression. More particularly, the present invention relates to a peptide marker for cancer diagnosis and a method for diagnosing cancer using the peptide marker, wherein glycoproteins aberrantly glycosylated due to cancer incidence and progression is isolated using lectin; and marker peptides generated by hydrolysis of the glycoproteins isolated by the lectin is selected and quantified.
Type:
Grant
Filed:
May 3, 2012
Date of Patent:
January 7, 2014
Assignee:
Korea Basic Science Institute
Inventors:
Yeong Hee Ahn, Jong Shin Yoo, Park Min Shin, Eun Sun Ji